Awards and Grants

Awards

2024 Paul I. Terasaki Clinical Science Award

The Paul I. Terasaki Clinical Science Award was established in 2003 to honor an individual, group, or institution in recognition of significant accomplishments and/or contributions to the fields of clinical transplantation, histocompatibility, and immunogenetics. This award was made possible by a grant from the Paul I. Terasaki Foundation and was presented to Dr. Tambur during the ASHI 50th Annual Meeting in Anaheim, California. 

2023 Rose Payne Award

The Rose Payne Award was established in 1984 to honor a great scientist and to recognize her long-standing contributions to the field of immunogenetics and her support in the development of the American Society for Histocompatibility & Immunogenetics (ASHI). Dr. Tambur received this prestigious award in 2023. 

2023 AST Distinguished Senior Career Award

The Distinguished Career Awards recognize clinicians and administrators with outstanding contributions to the field of transplantation. This award was given to Dr. Anat R. Tambur during the American Transplant Congress convention (ATC 2023) in San Diego, California.

2022 Bernard Amos Distinguished Scientist Award

In recognition of the scientific contributions to the field of immunogenetics and transplantation immunology made by Dr. Bernard Amos, this award was established in 2001 to honor a distinguished ASHI scientist, who like Dr. Amos, has made significant contributions to the field of histocompatibility and immunogenetics. Dr. Anat R. Tambur was a recipient of this award in 2022. 

Publication Awards

WILEY HLA: The Best Paper Award for Year 2024

Most influential/downloadable manuscript in 2024

Qualitative, rather than quantitative, differences between HLA-DQ alleles affect HLA-DQ immunogenicity in organ transplantation.

Maguire C., Crivello P., Fleischhauer K., Isaacson D., Casillas A., Kramer C.S.M., Copley H.C., Heidt S., Kosmoliaptsis V., Meneghini M., Gmeiner M., Schold J., Louzoun Y., & Tambur A.R.

HLA 2024 Apr;103(4):315455.  PMID:38575370.  doi:10.1111/tan.15455.

Best of ASN Journals Award 2022

HLA-DQ Mismatches Lead to More Unacceptable Antigens, Greater Sensitization, and Increased Disparities in Repeat Transplant Candidates.

Isaacson D., Schold J.D., Gmeiner M.W., Copley H.C., Kosmoliaptsis V., & Tambur A.R.

Journal of the American Society of Nephrology. 2022 Dec;33(12):2293-2305. PMID: 36450598. doi: 10.1681/ASN.2022030296.

AJT Top 10 Articles of 2019

The Quest to Decipher HLA Immunogenicity: Telling Friend from Foe

Tambur A.R., McDowell H., Hod-Dvorai R., Abundis M.A.C., & Pinelli D.F.

American Journal of Transplantation. 2019 June;19(5):2910-2925. doi:10.1111/ajt.15489.

Grants

 

2023 – 2028

Utility of Biomarkers of Rejection and Kidney Injury in Tailoring Liver Transplant Immunosuppression. National Institutes of Health (Sub-Investigator)

2023 – 2027

The Immunogenicity and Pathogenicity of HLA-DQ. National Institute of Allergy and Infectious Diseases (NIAID) – Principal Investigator.

2023 – 2024

Investigating HLA-DQ Immunogenicity: Site Directed Mutagenesis of Candidate Amino Acid Targets. Northwestern University – Comprehensive Transplant Center, The Dr. Michael M. Abecassis Transplant Innovation Endowment Grant

2022 – 2027

Comparison of High vs Standard Dose Influenza Vaccines in Lung Transplant Recipients. National Institute of Allergy and Infectious Diseases (NIAID) – Sub-Investigator (Halasa – Principal Investigator)

2022 – 2023

A Biomarker for Endothelial Health in Transplantation. Northwestern University – Comprehensive Transplant Center, The Dr. Michael M. Abecassis Transplant Innovation Endowment Grant (Co-Investigator)

2021 – 2022

Understanding the Immunogenicity of HLA-DQ Antibodies in Solid Organ Transplantation. Northwestern University – Comprehensive Transplant Center, The Dr. Michael M. Abecassis Transplant Innovation Endowment Grant

2020 – 2025

Comparison of High vs Standard Dose Influenza Vaccines in Adult Solid Organ Transplant Recipients. National Institute of Allergy and Infectious Diseases (NIAID) – Sub-Investigator (Halasa – Principal Investigator)

2020 – 2023

A Phase 1b/2 Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of Isatuxumab in Patients Awaiting Kidney Transplantation. Sanofi-Adventis

2020 – 2021

CRISPR/Cas9 Edited Singly Expressed HLA Class II Cells for the Study of HLA-DQ Immunogenicity. Northwestern University –Comprehensive Transplant Center, The Dr. Michael M. Abecassis Transplant Innovation Endowment Grant

2020 – 2025

Analyzing the Immunogenicity of HLA-DQ in Solid Organ Transplantation. Vanguard Charitable Endowment – Paul I. Terasaki fund

2018 – 2021

HLA-DQ Immunogenicity and its Role in Antibody Mediated Rejection in Solid Organ Transplantation. Paul I. Terasaki Research Foundation

2018 – 2023

Paul I. Terasaki Research Grant for HLA Director in Training Fellowship

2016 – 2020

Astagraf XL to Understand the Impact of Immunosuppression on De Novo DSA Development and Chronic Immune Activation in Kidney Transplantation. Astellas Pharma Global Development, Inc

2008 – 2011

A Phase 2, Multicenter, Open-label, Active Comparator-controlled, Extension Trial to Evaluate the Long-term Safety and Efficacy of CP-690,550 in Renal Allograft Recipient. A3921050-1046 (Investigator)

2008 – 2011

Induction of Donor Specific Tolerance in Recipients of Living Kidney Allografts by Donor Stem Cell Infusion. University of Louisville (Sub-Investigator)

2007 – 2010

Randomized Conversion of Calcineurin Inhibitor (Tacrolimus to Sirolimus) at 6-24 Months Post Transplant in a Prednisone-free Immunosuppression Regimen: Impact on Acute Rejection, Renal Allograft Function, and T Cell Function. Wyeth (Investigator)

2007 – 2008

Immune Tolerance Profiles after Conversion from Tacrolimus to Sirolimus in Liver Transplant Recipients. Wyeth (Investigator)

2007 – 2012

Donor Stem Cells, Campath, T/B Cell Regulation in HLA-Identical Renal Transplants. National Institutes of Health (Investigator)

2006 – 2011

CTOT-02: B Cell Depletion by Anti-CD20 (Rituximab) in Renal Allograft Recipients who Develop De Novo Anti-HLA Alloantibodies will Result in Inhibition of Alloantibody Production and Attenuation of Chronic Humoral Rejection. National Institutes of Health (DAIT, NIAID) (Sub-Investigator)

2006 – 2008

Immunophenotyping and Functional Profiles of Peripheral Lymphocytes in Renal Transplant Recipients after T-Cell Depletion with Alemtuzumab (Anti-CD52 Monoclonal Antibody) – Potential Implications for Safe Immunosuppressive Minimization. American Society of Transplantation (Sub-Investigator)

2006 – 2007

Desensitization for Highly Sensitized Recipients of Pancreas Transplantation. NMF (Co-Investigator)

2005 – 2007

Immunological Response to Stem Cell Transplantation. CINN (Co-Investigator)

2005 – 2009

A Phase IV, Single Center Pilot Study using Alemtuzumab (Campath-1H) Induction Combined with Prednisone-free and Calcineurin Inhibitor-free Immunosuppression in Kidney Transplantation. Roche(Investigator)

2005 – 2008

Desensitization of Crossmatch Positive Renal Transplant Recipients using Alemtuzumab. Ilex Oncology, Inc. (Co-Investigator)

2004

Photopheresis Treatment – Its Effects on Immune Cells. Theracos, Inc (Principal Investigator)

1999 – 2001

Risk Stratification of Heart Transplant Recipients by Flow Cytometry Detected Antibodies against Histocompatibility Molecules.  American Heart Association, Mid-west Affiliate; #9951446Z (Principal Investigator)

1998 – 1999

In-Vitro Protection of Human Lymphocytes and Neuronal Cells against Oxidation Damage by Ethoxyquine Phosphate and Propyl Gallate. Burlington Bio-Medical & Scientific Corporation (Principal Investigator)

1997 – 1998

The Role of Ultraviolet B Irradiation in Antigen Processing and Presentation.  University Committee on Research, Rush Medical College

1997 – 1998

Construction of Pgp-Deficient Cells. American Cancer Society, New Investigator Grant

1989 – 1991

Immunogenetics of Primary Sjogren’s Syndrome in Jewish Patients. Israel Ministry of Health, #1579